Latest Content

In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.

The New Jersey company recently announced the partnership that includes federal funding to create new treatments from a novel class of fungerps.

This week, read more about the first person with a novel avian influenza strain, doxyPEP linked to increased high-level tetracycline resistance, Ethiopia investigates Marburg virus disease outbreak, and more.

The World Health Organization (WHO) is assisting Ethiopia with experts, supplies, and emergency funding as the country investigates eight suspected cases of viral hemorrhagic fever in the South Ethiopia region.

James Conway, MD, describes how full vs partial repeal of nonmedical school-entry exemptions is associated with kindergarten vaccination and exemption trends.

Shionogi has been identifying in vitro activity using its antibiotic, cefiderocol, against Gram-negative clinical isolates such as carbapenem-resistant Enterobacterales (CRE). Christine Slover, PharmD, offers some insights on the company’s analysis.

A DOXYVAC substudy found higher rates of tetM-mediated tetracycline resistance and more isolates with decreased cefixime susceptibility among MSM using doxycycline PEP.

This is the first human ever known to be infected with the H5N5 strain. The infected patient was from Washington state, and was undergoing treatment for H5N5 (avian influenza) when the individual died last week.

New modeling and clinical data presented by Atea Pharmaceuticals suggest that its fixed-dose combination of bemnifosbuvir and ruzasvir could offer a potent, short-duration, best-in-class treatment option for hepatitis.

The 2025 World Health Organization's (WHO) Global Tuberculosis Report finds progress in prevention, diagnosis, and care—but falling short of targets and curtailed by funding cuts.

This week, read about Merck's advancement of one of its HIV combination therapeutics, Pfizer's influenza vaccine data, the importance of antimicrobial resistance awareness, and more.

Large international study reports higher A-strain protection and acceptable safety profile for quadrivalent RNA influenza vaccine.

A mother recounts her newborn son's fatal battle with cirrhosis reminding people of the importance of health and education about this vital organ.